NRX PHARMACEUTICALS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$1M
Cost of Revenue
$505K
R&D
$4M
SG&A
$13M
D&A
$70K
Operating Income
$-16M
EBITDA
$-16M
Interest Expense
$671K
Interest Income
$12K
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income
$-29M
Operating Margin
-1324.4%
Net Margin
-2336.5%
Effective Tax Rate
—
Deferred Tax Assets
—
Deferred Tax Liabilities
$2K
DTA Valuation Allowance
$51M
NOL Carryforwards
$44M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.2%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$109K
Revenue YoY Variation
—
Income YoY Variation
12.3%